期刊文献+

甲状腺乳头状癌的外科治疗探讨 被引量:4

Surgical treatment of papillary thyroid carcinoma
下载PDF
导出
摘要 目的探讨甲状腺乳头状癌(PTC)的外科治疗相关问题。方法对100例PTC手术治疗病例临床资料进行回顾性分析。结果对100例患者中发现124个癌灶,多灶性甲状腺癌17例(占17.0%),颈部淋巴结转移40例(40.0%);合并结节性甲状腺肿﹑桥本病﹑滤泡型腺瘤36例(36.0%)。手术方式包括:甲状腺患侧叶切除术52例,患侧全切加对侧大部分切除术33例,甲状腺全切15例,中央区淋巴清扫术100例,侧颈部淋巴清扫术37例。术后并发症发生率7.0%;术后1例同侧颈淋巴结转移,1例对侧甲状腺出现癌灶。结论应根据PTC患者病变的不同部位及数目(单发/多发)及有无淋巴结转移采用相应的手术方式。 Objective To explore the relative problem of surgical treatments of papillary thyroid carcinoma (PTC). Methods Clinical data of 100 cases of PTC were analyzed retrospectively. Results Among 100 cases,there were 124 cancers, 17 cases( 17.0% ) of thyroid cancer with multifocal differentiated carcinomas ;40 cases (40.0%) of metastasis in cervical lymph nodes;and 36 cases(36.0% ) of co-existence of multinodular goiter,Hashimoto disease or follicular adenoma. Various operative procedures were used in the treatment of 100 cases of thyroid microcarcinoma that included excision of the affected lobe in 47 cases, excision of the affected lobe and greater part of the opposite lobe in 33 cases, total thyroideetomy in 15 cases. Central compartment neck dissection 100 cases, bilateral total resection combined with neck dissection. The incidence rate of complications after surgery was 7.0%, 1 case had metastatic cervical lymph nodes at the same side. 1 case had focal cancer at the other side. Conclusion The selection of operative procedure for thyroid microcarcinoma must be determined according to the tumor location of tumor and the number ( single or multiple).
出处 《中国临床保健杂志》 CAS 2012年第3期243-245,共3页 Chinese Journal of Clinical Healthcare
关键词 甲状腺肿瘤 甲状腺切除术 回顾性研究 Thyroid neoplasms Thyroidectomy Retrospective studies
  • 相关文献

参考文献8

二级参考文献21

  • 1殷德涛,王庆兆.分化型甲状腺癌的治疗[J].中国普通外科杂志,2007,16(1):7-9. 被引量:38
  • 2Jemal A, Siegel R, Ward E,et al. Cancer statistics,2009 [J].CA Cancer J Clin,2009,59(4):225-249.
  • 3Cooper DS, Doherty GM,Haugen BR, et al. Revised American Thyroid Association ManagementGuidelines for Patients with Thyroid Nodulesand Differentiated Thyroid Cancer [J].Thyroid, 2009, 19(11):1167-1214.
  • 4NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma[S/OL]. Version 1.2011.http://www.nccn.org/professionals/ physician_gls/pdf/thyroid.pdf.
  • 5Pacini F, Castagna MG, Pentheroudakis LBG.Thyroid cancer: ESMO clinical practice guidelines fordiagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 21(suppl 5): 214-219.
  • 6Coburn MC, Wanebo HJ.Prognosis factors and management of thyroid cancer.Am J Surg, 1992, 164:671-676.
  • 7Sanders LE, Cady B.Differentiated thyroid cancer.Archives of Surg, 1998, 133:419-425.
  • 8Cady B.How an old concept still hits the mark:or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer.Am J Surg, 1997, 174 :462-468.
  • 9Mazzaferri EL.An overview of the management of papillary and follicular thyroid carcinoma.Thyroid, 1999, 9 :421-427.
  • 10Sebastian SO, Gonzalez JM, Paricio PP.Papillary thyroid carcinoma :prognostic index survival.Arch Surg, 2000, 135 :272-277.

共引文献201

同被引文献26

  • 1赵亚萍,王鑫.甲状腺乳头状癌的超声图像特征与病理分析[J].医学影像学杂志,2012,22(2):274-275. 被引量:11
  • 2Eloy C, Santos J, Cameselle-Teijeiro J, et al, TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch,2012, 460(6) :587-600.
  • 3Tran Cao HS, Johnston LE, Chang DC, et al. A critical analysis of the American Joint Committee on Cancer (AJCC) staging sys- tem for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results ( SE- ER) registry. Surgery,2012,152(2) :145-151.
  • 4Mondul AM, Weinstein SJ, Bosworth T, et al. Circulating thyrox- ine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoS One,2012,7(10) :e47730.
  • 5Hart JM, Kim WB, Yim JH, et al. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid ,2012, 22 ( 8 ) :784-790.
  • 6Ito M, Miyauchi A, Morita S, et al. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum trii- odothyronine levels in patients who have undergone total thyroidec- tomy. Eur J Endocrino1,2012,167 (3) :373-378.
  • 7Tanaka K, Sonoo H. Current trends in TSH suppression therapy for patients with papillary thyroid carcinoma in Japan : results of a questionnaire distributed to councilors of the Japanese Society of Thyroid Surgery. Surg Today,2012,42(7) :633-638.
  • 8Lee EK, Chung KW, Min HS, et al. Preoperative serum thyro- globulin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules. J Korean Med Sci ,2012,27 (9) : 1014-1018.
  • 9Okamoto T,Yamashita T,Harasawa A,et al.Test performances of three diagnostic procedures in evaluating thyroid nodules:physical examination, ultrasonography and fine needle aspiration cytology[J]. Endocrine Journal, 1994,41 (3):243-247.
  • 10Saeed N,Amirhosein H A.Comparison of Results of Ultrasound and FNA in Thyroid Nodules[J]. Iranian Journal of Radiology, 2011,8(1):68-72.

引证文献4

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部